ULN (2.1%) have also been reported. Hepatitis, hepatic failure , hepatic cytolysis , pancreatitis (including at least one case with lactic acidosis ), jaundice , liver function abnormalities , increased serum triglycerides , and cirrhosis have been reported in postmarketing experience with indinavir. Gastrointestinal side effects have included nausea (12%), diarrhea (3.3%),